Reporting from: – San Antonio Breast Cancer Symposium, December 8-11, 2004 – European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna In this edition: Raimund J
Reporting from:
– San Antonio Breast Cancer Symposium, December 8-11, 2004
– European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna
In this edition:
Raimund Jakesz discusses the results from a combined Austrian and German study, examining the effects of switching from tamoxifen to an aromatase inhibitor in approximately 3,000 women with breast cancer.
Tony Howell talks about latest results from the ATAC trial, designed to find out whether single-agent tamoxifen or single-agent anastrazole is better at five years. Dr. Howell reports on study results at 68 months of follow-up for more than 9,000 postmenopausal women.
Thomas B. Julian gives the latest findings from the large American NSABP B-32 trial, which compared sentinel node biopsy with conventional axillary dissection.
Robert Mansel reports results from the British ALMANAC study involving 1,031 patients. This longest-running study of sentinel node biopsy comparing the method with standard axillary treatment closed in 2003.
Ivo Olivotto addresses the question of which patients having mastectomy should receive radiation, particularly if a woman has one to three positive nodes. His group analyzed data on approximately 820 women referred between 1989 and 1997, treated with mastectomy.
…
Related Episodes
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
Xiuning Le MD PhD; ESMO 2025: Sevabertinib Success for Patients with HER2-Mutated Non-Small Cell Lung Cancer in SOHO-01 Study
A new anti cancer drug sevabertinib, that targets mutated HER2, has proved effective in the SOHO-01 study among patients wiith HER2 mutated non small cell lung cancer. It has now been reported in the